Foghorn Therapeutics Inc. — Form 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics filed a Current Report on Form 8-K dated April 16, 2024, reporting an executive officer appointment and related management transition. The filing does not present quarterly or annual financial results.
Key Financial and Operating Information
- Kristian F. Humer was appointed Chief Financial Officer, principal financial officer, and principal accounting officer, effective immediately.
- Stephen DiPalma ceased serving in those roles in connection with the appointment.
- The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes and Compensation Terms
- Mr. Humer’s employment agreement provides for an annual base salary of $475,000.
- He is eligible for an annual performance bonus targeted at 40% of annual base salary.
- He will receive a signing bonus of $87,000, less applicable deductions and withholdings.
- The company will grant an option to purchase 275,000 shares under its 2020 Equity Incentive Plan. The exercise price will equal the company’s closing stock price on the grant date.
- The option vests 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters, subject to continued employment.
Management Commentary, Outlook, and Risks
The filing includes biographical information regarding Mr. Humer, including his prior service as Chief Financial and Chief Business Officer of Viridian Therapeutics and healthcare investment banking experience at Citi. It does not provide financial guidance, business outlook, clinical updates, or new risk disclosures.
The appointment creates additional compensation and equity dilution exposure. The ultimate value and dilution from the option award will depend on the grant date, share price, vesting, and any future exercise. The filing states that there are no arrangements or understandings relating to Mr. Humer’s appointment, no family relationships with company directors or officers, and no related-party transaction involving him.
Important Facts for Investors to Verify
- Verify the final option grant date, exercise price, and share count in subsequent filings.
- Review Exhibit 10.1 for the complete employment agreement and any termination or change-in-control provisions.
- Monitor future filings for the impact of the CFO transition on financial reporting, liquidity disclosures, and corporate guidance.
- Confirm whether any additional compensation or equity awards are disclosed in the company’s next proxy statement or periodic report.